MYL’s price movements
On January 8, Mylan (MYL) closed at $29.87, up 0.40% from its previous closing price. The company closed at a premium of 14.73% to its 52-week low price of $26.03 and at a discount of 37.54% to its 52-week high price of $47.82. As of January 8, Mylan’s market cap is $15.37 billion. The company is trading at a trailing PE ratio of 24.13x and a forward PE ratio of 5.85x.
Based on its closing price on January 8, the company had reported returns of 9.01% in the last week, -6.19% in the last month, and -15.36% in the last quarter. It had also reported returns of -19.51% in the last half year, -32.94% in the last year, and 9.01% YTD (year-to-date).
Based on its closing price on January 7, the US healthcare sector represented by the Vanguard Health Care ETF (VHT) had reported returns of 1.47% in the last week, -6.03% in the last month, and -8.31% in the last quarter. VHT had also reported returns of -1.45% in the last half year, 2.56% in the last year, and 1.47% YTD.
Analysts’ recommendations and target prices for Mylan
The 12-month consensus analyst recommendation for Mylan as of January 9 is a “buy.” The 12-month consensus target price for the company is $42.63, 42.72% higher than its closing price on January 8. The highest target price estimate for the company is $55, and the lowest target price estimate is $28.
Of the 17 analysts covering Mylan on January 9, seven analysts have rated the company as a “strong buy,” six have rated it as a “buy,” and four have rated it as a “hold.”
In the next article, we’ll compare the revenue growth prospects of Teva Pharmaceutical and Mylan in greater detail.